Reports
Sale
Latin America Hemoglobinopathies Market Size, Share, Growth: By Type: Thalassemia, Sickle Cell Disease, Other Hb Variants Diseases; By Treatment: Stem-Cell Transplantation, Blood Transfusions, Analgesics, Antibiotics, Ace Inhibitors, Hydroxyurea, Others; By Test Type; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Latin America Hemoglobinopathies Market Size
The global hemoglobinopathies market valued at USD 6.9 billion in 2023, with Latin America holding a significant market share. It is expected to grow at a CAGR of 9.7% during the forecast period of 2024-2032. The market is poised to secure a market value of USD 7.5 billion by 2032, driven by the rising incidence of thalassemia and sickle cell anemia across the region.
Latin America Hemoglobinopathies Market Outlook
- The rising incidence of sickle cell disease (SCD) and thalassemia, which are amongst the most prevalent hemoglobinopathies boosting the market demand in Latin American region.
- In November 2023, the IAEA trained over 30 Latin American and Caribbean health experts in blood irradiation, enhancing regional safety, standardization, and collaboration in medical practices. Such initiatives to drive awareness amongst healthcare providers is one of the significant Latin America hemoglobinopathies market trends.
- In December 2023, University of Maryland School of Medicine researchers discussed new sickle cell disease treatments at a symposium in Rio De Janeiro, Brazil, addressing the disease affecting 20 million globally. The establishment of such events underscores the emphasis on managing and treating hemoglobinopathies effectively.
Latin America Hemoglobinopathies Market Analysis
Hemoglobinopathies are a group of inherited blood disorders, affecting hemoglobin in the red blood cells. They are often caused by genetic mutations that lead to alteration of hemoglobin structure, function, or production. Sickle cell anemia and thalassemia are amongst the most common types of hemoglobinopathies. Sickle cell disease (SCD) is a group of hereditary chronic diseases that has significantly reduced the quality of life. The prevalence of HbS, (sickle hemoglobin) is quite common in Colombia, predominantly affecting males. The ancestry has influenced the distribution of hemoglobinopathies in different geographical regions of Colombia, driving the increasing number of cases in the market. Thalassemia is one of the common hemoglobinopathies as well.
The Latin America hemoglobinopathies market growth is expected to be driven by the increasing focus of researchers on developing effective treatments for hemoglobinopathies such as thalassemia and sickle cell disease. Researchers are more inclined toward finding and delivering the best technique, technology, and treatment for the management of chronic disease, propelling the market demand. For instance, in December 2023, University of Maryland School of Medicine (UMSOM) dean joined prominent scientists and government health officials at a symposium in Rio De Janeiro, Brazil, to discuss new treatments for sickle cell disease (SCD). The symposium highlighted the developments undergoing in a randomized multicenter clinical trial for Sickle Cell Disease and CardiovAscular Risk-Red Cell Exchange Trial (SCD-CARRE), conducted across 22 sites in Brazil, France, and the United States. Such events are projected to boost the Latin America hemoglobinopathies market share as conducting it among the diverse population of Brazil will not only make the trial challenging but rather contribute to increased efficiency and accuracy, helpful in becoming a standard treatment option.
The market is poised to be driven by the strategic initiatives of organisations to train health practitioners on safe blood irradiation practices. For instance, in November 2023, the International Atomic Energy Agency (IAEA) organized a regional training course on the safe delivery of blood irradiation services for health practitioners in Latin America and the Caribbean. 30+ experts from domains such as hematology, biochemistry, physics, quality assurance, and radiation technology were gathered to update and share their knowledge, and best practices, and learn from each other’s experiences. The emphasis on delivering immediate and quality care to the patients is one of the major Latin America hemoglobinopathies market trends expected to boost the market value positively in the forecast period.
Patients suffering from hemoglobinopathies like thalassemia and sickle cell disease require frequent blood transfusions. This training ensures that health practitioners are well-trained in delivering safer blood transfusions. Improved safety and efficacy of transfusions directly enhance patient outcomes and could lead to increased trust and reliance on transfusion services. This is likely to impact the market positively by improving the quality of care and increasing awareness about the necessary measures required to be taken during the process.
Latin America Hemoglobinopathies Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
| Market Breakup | Categories |
| Type | Thalassemia, Sickle Cell Disease, Other Hb Variant Diseases |
| Treatment | Stem-Cell Transplantation, Blood Transfusions, Analgesics, Antibiotics, Ace Inhibitors, Hydroxyurea, Monoclonal Antibody Medication, Others |
| Test Type | Routine Red Blood Cell (RBC) Count, Genetic Testing, Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC), Hemoglobin Isoelectric Focusing (Hb IEF), Hemoglobin Electrophoresis (Hb ELP), and Hemoglobin Solubility Test |
| End User | Hospitals, Clinics, Diagnostic Laboratories, Others |
| Country | Brazil, Argentina, Mexico, Others |
Latin America Hemoglobinopathies Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Abbott
- Alnylam Pharmaceuticals, Inc.
- Biogen
- Bristol-Myers Squibb Company
- Danaher
- Emmaus Medical, Inc.
- F. Hoffmann-La Roche Ltd
- Gamida Cell
- Global Blood Therapeutics, Inc.
- Novartis
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Treatment |
|
| Breakup by Test Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Latin America Hemoglobinopathies Market Overview
3.1 Latin America Hemoglobinopathies Market Historical Value (2017-2023)
3.2 Latin America Hemoglobinopathies Market Forecast Value (2024-2032)
4 Latin America Hemoglobinopathies Market Landscape*
4.1 Latin America Hemoglobinopathies: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Latin America Hemoglobinopathies: Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Treatment
5 Latin America Hemoglobinopathies Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Latin America Hemoglobinopathies Market Segmentation (2017-2032)
6.1 Latin America Hemoglobinopathies Market (2017-2032) by Type
6.1.1 Market Overview
6.1.2 Thalassemia
6.1.3 Sickle Cell Disease
6.1.4 Other Hb Variants Diseases
6.2 Latin America Hemoglobinopathies Market (2017-2032) by Treatment
6.2.1 Market Overview
6.2.2 Stem-Cell Transplantation
6.2.3 Blood Transfusions
6.2.4 Analgesics
6.2.5 Antibiotics
6.2.6 Ace Inhibitors
6.2.7 Hydroxyurea
6.2.8 Monoclonal Antibody Medication
6.2.9 Others
6.3 Latin America Hemoglobinopathies Market (2017-2032) by Test Type
6.3.1 Market Overview
6.3.2 Routine Red Blood Cell (RBC) Count
6.3.3 Genetic Testing
6.3.4 Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
6.3.5 Hemoglobin Isoelectric Focusing (Hb IEF)
6.3.6 Hemoglobin Electrophoresis (Hb ELP)
6.3.7 Hemoglobin Solubility Test
6.4 Latin America Hemoglobinopathies Market (2017-2032) by End User
6.4.1 Market Overview
6.4.2 Hospitals and Clinics
6.4.3 Diagnostics Laboratories
6.4.4 Others
6.5 Latin America Hemoglobinopathies Market (2017-2032) by Country
6.5.1 Market Overview
6.5.2 Brazil
6.5.3 Argentina
6.5.4 Mexico
6.5.5 Others
7 Brazil Hemoglobinopathies Market (2017-2032)
7.1 Brazil Hemoglobinopathies Market (2017-2032) by Type
7.1.1 Market Overview
7.1.2 Thalassemia
7.1.3 Sickle Cell Disease
7.1.4 Other Hb Variants Diseases
7.2 Brazil Hemoglobinopathies Market (2017-2032) by Treatment
7.2.1 Market Overview
7.2.2 Stem-Cell Transplantation
7.2.3 Blood Transfusions
7.2.4 Analgesics
7.2.5 Antibiotics
7.2.6 Ace Inhibitors
7.2.7 Hydroxyurea
7.2.8 Monoclonal Antibody Medication
7.2.9 Others
7.3 Brazil Hemoglobinopathies Market (2017-2032) by Test Type
7.3.1 Market Overview
7.3.2 Routine Red Blood Cell (RBC) Count
7.3.3 Genetic Testing
7.3.4 Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
7.3.5 Hemoglobin Isoelectric Focusing (Hb IEF)
7.3.6 Hemoglobin Electrophoresis (Hb ELP)
7.3.7 Hemoglobin Solubility Test
7.4 Brazil Hemoglobinopathies Market (2017-2032) by End User
7.4.1 Market Overview
7.4.2 Hospitals and Clinics
7.4.3 Diagnostics Laboratories
7.4.4 Others
8 Argentina Hemoglobinopathies Market (2017-2032)
8.1 Argentina Hemoglobinopathies Market (2017-2032) by Type
8.1.1 Market Overview
8.1.2 Thalassemia
8.1.3 Sickle Cell Disease
8.1.4 Other Hb Variants Diseases
8.2 Argentina Hemoglobinopathies Market (2017-2032) by Treatment
8.2.1 Market Overview
8.2.2 Stem-Cell Transplantation
8.2.3 Blood Transfusions
8.2.4 Analgesics
8.2.5 Antibiotics
8.2.6 Ace Inhibitors
8.2.7 Hydroxyurea
8.2.8 Monoclonal Antibody Medication
8.2.9 Others
8.3 Argentina Hemoglobinopathies Market (2017-2032) by Test Type
8.3.1 Market Overview
8.3.2 Routine Red Blood Cell (RBC) Count
8.3.3 Genetic Testing
8.3.4 Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
8.3.5 Hemoglobin Isoelectric Focusing (Hb IEF)
8.3.6 Hemoglobin Electrophoresis (Hb ELP)
8.3.7 Hemoglobin Solubility Test
8.4 Argentina Hemoglobinopathies Market (2017-2032) by End User
8.4.1 Market Overview
8.4.2 Hospitals and Clinics
8.4.3 Diagnostics Laboratories
8.4.4 Others
9 Mexico Hemoglobinopathies Market (2017-2032)
9.1 Mexico Hemoglobinopathies Market (2017-2032) by Type
9.1.1 Market Overview
9.1.2 Thalassemia
9.1.3 Sickle Cell Disease
9.1.4 Other Hb Variants Diseases
9.2 Mexico Hemoglobinopathies Market (2017-2032) by Treatment
9.2.1 Market Overview
9.2.2 Stem-Cell Transplantation
9.2.3 Blood Transfusions
9.2.4 Analgesics
9.2.5 Antibiotics
9.2.6 Ace Inhibitors
9.2.7 Hydroxyurea
9.2.8 Monoclonal Antibody Medication
9.2.9 Others
9.3 Mexico Hemoglobinopathies Market (2017-2032) by Test Type
9.3.1 Market Overview
9.3.2 Routine Red Blood Cell (RBC) Count
9.3.3 Genetic Testing
9.3.4 Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
9.3.5 Hemoglobin Isoelectric Focusing (Hb IEF)
9.3.6 Hemoglobin Electrophoresis (Hb ELP)
9.3.7 Hemoglobin Solubility Test
9.4 Mexico Hemoglobinopathies Market (2017-2032) by End User
9.4.1 Market Overview
9.4.2 Hospitals and Clinics
9.4.3 Diagnostics Laboratories
9.4.4 Others
10 Regulatory Framework
11 Patent Analysis
11.1 Analysis by Type of Patent
11.2 Analysis by Publication Year
11.3 Analysis by Issuing Authority
11.4 Analysis by Patent Age
11.5 Analysis by CPC Analysis
11.6 Analysis by Patent Valuation
11.7 Analysis by Key Players
12 Grants Analysis
12.1 Analysis by Year
12.2 Analysis by Amount Awarded
12.3 Analysis by Issuing Authority
12.4 Analysis by Grant Application
12.5 Analysis by Funding Institute
12.6 Analysis by Departments
12.7 Analysis by Recipient Organization
13 Funding and Investment Analysis
13.1 Analysis by Funding Instances
13.2 Analysis by Type of Funding
13.3 Analysis by Funding Amount
13.4 Analysis by Leading Players
13.5 Analysis by Leading Investors
13.6 Analysis by Geography
14 Partnership and Collaborations Analysis
14.1 Analysis by Partnership Instances
14.2 Analysis by Type of Partnership
14.3 Analysis by Leading Players
14.4 Analysis by Geography
15 Supplier Landscape
15.1 Market Share by Top 5 Companies
15.2 Abbott
15.2.1 Financial Analysis
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Alnylam Pharmaceuticals, Inc.
15.3.1 Financial Analysis
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Biogen
15.4.1 Financial Analysis
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Bristol-Myers Squibb Company
15.5.1 Financial Analysis
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Danaher
15.6.1 Financial Analysis
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Emmaus Medical, Inc.
15.7.1 Financial Analysis
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 F. Hoffmann-La Roche Ltd
15.8.1 Financial Analysis
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
15.9 Gamida Cell
15.9.1 Financial Analysis
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.9.5 Certifications
15.10 Global Blood Therapeutics, Inc.
15.10.1 Financial Analysis
15.10.2 Product Portfolio
15.10.3 Demographic
15.10.4 Mergers and Acquisitions
15.10.5 Certifications
15.11 Novartis
15.11.1 Financial Analysis
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.11.5 Certifications
16 Latin America Hemoglobinopathies Market – Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Key Opinion Leaders (KOL) Insights (Additional Insight)
18 Company Competitiveness Analysis (Additional Insight)
18.1 Very Small Companies
18.2 Small Companies
18.3 Mid-Sized Companies
18.4 Large Companies
18.5 Very Large Companies
19 Payment Methods (Additional Insight)
19.1 Government Funded
19.2 Private Insurance
19.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The Latin America hemoglobinopathies market is expected to be driven by the rising demand in the global market, which is anticipated to grow at a CAGR of 9.7% during the forecast period of 2024-2032 and is likely to reach a market value of USD 15.9 billion by 2032.
The increasing number of research activities to find new treatments for sickle cell disease and thalassemia are driving the market demand.
Organisations like the IAEA conducting training sessions for healthcare practitioners to learn the best practices from experts is a major trend influencing market growth.
Different types of hemoglobinopathies in the market are thalassemia, sickle cell disease and other Hb variant diseases.
Treatments available for hemoglobinopathies include stem-cell transplantation, blood transfusions, analgesics, antibiotics, ace inhibitors, hydroxyurea, monoclonal antibody medication, and others.
Type of tests includes routine red blood cell (RBC) Count, genetic testing, hemoglobin by high performance liquid chromatograph (Hb HPLC), hemoglobin isoelectric focusing (Hb IEF), hemoglobin electrophoresis (Hb ELP), and hemoglobin solubility test.
End users in the market include hospitals and clinics, and diagnostic laboratories among others.
The market segmentation by countries include Brazil, Argentina, Mexico, and others.
The key players in the market are Abbott, Alnylam Pharmaceuticals, Inc., Biogen, Bristol-Myers Squibb Company, Danaher, Emmaus Medical, Inc., F. Hoffmann-La Roche Ltd, Gamida Cell, Global Blood Therapeutics, Inc., and Novartis.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER